Abstracts tagged "sarcopenia and systemic vasculitides"

Abstract Number: 2730 • 2018 ACR/ARHP Annual Meeting
Handgrip Strength Predicts the Risk of Bone Fracture and Severe Adverse Events in Patients with Systemic Necrotizing Vasculitis
Soledad Henriquez¹, Bertrand Dunogué², Raphaël Porcher³, Alexis Régent¹, Pascal Cohen⁴, Alice Bérezné¹, Sami Kolta⁵, Claire Le Jeunne¹, Luc Mouthon⁶, Christian Roux⁵, Loïc Guillevin⁷, Karine Briot⁸ and Benjamin Terrier⁹, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²Internal Medicine, Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Université Paris Descartes Sorbonne Paris, Paris, France, ⁴Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ⁵Department of Rheumatology, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁶Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ⁷Medecine Interne, Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁸Department of Rheumatology, Cochin Hospital and Epidemiology and Biostatistics Unit,Sorbonne Paris Cité Reserach Center,Paris Descartes University,INSERM U1153, Paris, France, ⁹National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France
Background/Purpose: Sarcopenia, characterized by progressive loss of both muscle mass and muscle strength, has been associated with poor outcomes in various diseases. Muscle weakness is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].